secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K/A
Filed at:   2026-11-10T21:30:18+00:00
Accession:  0001214659-26-013930
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Alzamend trims Ault Lending preferred facility to $10M from $25M; $2.5M second tranche remains
--------------------------------------------------------------------------------

- Amended and restated Nov 10, 2026 purchase pact with Ault Lending, LLC, an affiliate, cuts total Series D convertible preferred sale to $10M from $25M.
- $7.5M initial tranche (7,500 shares at $1,050 stated value) closed July 31, 2026; $2.5M second tranche of 2,500 shares remains, 15 planned $1M monthly closings eliminated.
- Conversion price is the greater of a $0.2668 floor or 80% of the lowest 5-day closing bid (cap $2.00), with full-ratchet reset to the floor; voting floor $1.4175 vs $1.35 close.
- Resale registration due Nov 17, 2026; misses trigger 2% monthly liquidated damages capped at 15%; stockholder vote sought for shares above the 19.99% Nasdaq limit.
- 2% origination fee payable at each tranche closing; Purchaser holds a 3-year right of first refusal and 33.33% participation right on future financings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926013930/0001214659-26-013930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926013930/o11102668ka1.htm
  HTML page:      https://secwatch.observer/filing/0001214659-26-013930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer